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Abstract
Background: Success of metabolomics as the phenotyping platform largely depends on its ability
to detect various sources of biological variability. Removal of platform-specific sources of variability
such as systematic error is therefore one of the foremost priorities in data preprocessing.
However, chemical diversity of molecular species included in typical metabolic profiling
experiments leads to different responses to variations in experimental conditions, making
normalization a very demanding task.
Results: With the aim to remove unwanted systematic variation, we present an approach that
utilizes variability information from multiple internal standard compounds to find optimal
normalization factor for each individual molecular species detected by metabolomics approach
(NOMIS). We demonstrate the method on mouse liver lipidomic profiles using Ultra Performance
Liquid Chromatography coupled to high resolution mass spectrometry, and compare its
performance to two commonly utilized normalization methods: normalization by l2 norm and by
retention time region specific standard compound profiles. The NOMIS method proved superior
in its ability to reduce the effect of systematic error across the full spectrum of metabolite peaks.
We also demonstrate that the method can be used to select best combinations of standard
compounds for normalization.
Conclusion:  Depending on experiment design and biological matrix, the NOMIS method is
applicable either as a one-step normalization method or as a two-step method where the
normalization parameters, influenced by variabilities of internal standard compounds and their
correlation to metabolites, are first calculated from a study conducted in repeatability conditions.
The method can also be used in analytical development of metabolomics methods by helping to
select best combinations of standard compounds for a particular biological matrix and analytical
platform.
Background
Metabolomics is a discipline dedicated to the global study
of metabolites, their dynamics, composition, interactions,
and responses to interventions or to changes in their envi-
ronment, in cells, tissues, and biofluids. Concentration
changes of specific groups of metabolites may be descrip-
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tive of systems responses to environmental or genetic
interventions, and their study may therefore be a powerful
tool for characterization of complex phenotypes [1-3] as
well as for development of biomarkers for specific physi-
ological responses [4,5].
Study of the variability of metabolites in different states of
biological systems is therefore an important task of sys-
tems biology. As we are primarily interested in systems
responses resulting in metabolite level regulation as
related to diverse genetic or environmental changes, it is
important to separate such interesting biological variation
from obscuring sources of variability introduced in experi-
mental studies of metabolites. Since multiple experimen-
tal platforms are commonly applied in the studies of
metabolites [6,7], the sources of the obscuring variation
are many and platform specific [8]. Such sources include
variability arising from inhomogeneity of samples, their
lability and inevitable minor differences in sample prepa-
ration. In mass spectrometry based detection, the sources
include the variations in the ion source as well as matrix
specific effects such as ion suppression [9]. Following the
measurement, the data preprocessing steps such as peak
detection, peak integration and alignment may introduce
an additional error.
Chemical diversity of metabolites, leading for example to
different recoveries during extraction or responses during
ionization in mass spectrometer, makes separation of
interesting and obscuring variation a difficult task. Quan-
titative analytical methods have commonly relied on uti-
lization of isotope labeled internal standard for each
metabolite measured. However, in broad metabolic pro-
filing approaches this is not practical. The number of
metabolites is large, they are chemically too diverse to
afford a common labeling approach, and many of them
may not even be known. The availability of stable isotope
labeled references is generally also very limited.
Strategies for normalization of metabolic profile data can
be divided into two major categories:
￿ Statistical models used to derive optimal scaling factors
for each sample based on complete dataset [10], such as
normalization by unit norm [11] or median [12] of inten-
sities, or the maximum likelihood method [2] adopted
from the approach developed for gene expression data
[13].
￿ Normalization by a single or multiple internal or exter-
nal standard compounds based on empirical rules, such
as specific regions of retention time [14].
The statistical approach suffers from the lack of an abso-
lute concentration reference for different metabolites. In
addition, constraining the data to a specific norm based
on total signal affects its covariance structure, therefore
requiring special caution when pursuing multivariate
analysis of such data [15]. Metabolites as physiological
end-points, largely affected by the environment, do not
posses the self-averaging  property, i.e. concentration
increase in a specific group of metabolites is generally not
balanced by a decrease of another group. The Figure 1
illustrates this statement. Two total ion chromatograms
from Ultra Performance Liquid Chromatography coupled
to Mass Spectrometry (UPLC/MS) lipidomics profiling of
two different mouse liver samples are shown, one from an
obese ob/ob mouse model and one from a lean wild type
mouse. The ob/ob mouse model was developed by spon-
taneous mutation in ob gene resulting in lack of leptin
[16] and is commonly studied as a model for early onset
of severe obesity. Both types of mice have similar levels of
phospholipids, but the amount of storage fat in the form
of triacylglycerols is markedly increased in the obese
mouse. If one would normalize this data based on total
signal, such approach would lead to a conclusion that the
phospholipids are decreased in the obese mouse (wrong
conclusion), while the triacylglycerols are slightly
increased (correct qualitatively, but not quantitatively).
More sophisticated approaches to normalize metabo-
lomics data based on full profile data have been adopted
[2], but the fundamental problem as described above
remains.
The choice of multiple internal (added to sample prior to
extraction) and external (added to sample after extrac-
tion) standard compounds may be a more reasonable
choice, but even in that case the assignment of the stand-
ards to normalize specific peaks remains unclear. One
possible approach is to assign a specific standard to
metabolite peaks based on similarity in specific chemical
property such as retention time in liquid chromatography
(LC) column. For example, Bijlsma and colleagues utilize
three external standard references for lipid profiling, cho-
sen as mono-, di-, and tri-acyl lipid species representing
most abundant lipid classes in their respective region of
retention time [14]. Such approach still suffers from at
least two problems:
￿ The retention time is not necessarily descriptive of all
matrix and chemical properties leading to obscuring vari-
ation. For example, in the lipid separation based on
reverse phase LC diverse lipid species such as ceramides,
sphingomyelins, diacylglycerols, and several phospholi-
pid classes, are overlapping in retention time, and it is not
reasonable to assume same normalization factor can be
applied to all these species. The situation is even more
complex when analyzing water soluble metabolites.BMC Bioinformatics 2007, 8:93 http://www.biomedcentral.com/1471-2105/8/93
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￿ The normalization by a single molecular component is
very sensitive to its own obscuring variation, which
becomes a problem in very complex samples where
matrix specific effects such as ion suppression may play an
important role.
Recently we introduced a related approach for liquid chro-
matography – mass spectrometry (LC/MS) that normal-
izes metabolites based on multiple internal standards,
with the normalization factor based on distance to the
metabolite peaks both in the retention time and mass-to-
charge ratio (m/z) [17]. While such method partially
resolves the second issue listed above, it still suffers from
the ad hoc assignments of internal standard(s) for each
component based on a subset of relevant chemical prop-
erties.
None of the normalization methods mentioned above
systematically take advantage of the obscuring variability
that can be learned from the measured data itself. For
example, monitoring multiple standard compounds
across multiple sample runs may help determine how the
Comparing two metabolomic total ion chromatograms (TIC) from two different mouse phenotypes Figure 1
Comparing two metabolomic total ion chromatograms (TIC) from two different mouse phenotypes. An illus-
trative example of how normalization of metabolomics data based on total signal may generate bias in the data. Two mouse 
liver lipid profiles are drawn to scale, one from obese ob/ob mouse and one from lean wild type mouse. While the phospholi-
pid profiles are similar in total amount, there is a large increase in triacylglycerols in obese mouse. Normalization based on 
total signal would wrongfully decrease the levels of phospholipids in obese mouse relative to the wild type to balance the 
increased amount of triacylglycerols.BMC Bioinformatics 2007, 8:93 http://www.biomedcentral.com/1471-2105/8/93
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standards are correlated, which variation is specific to a
particular standard, and which patterns of variation are
shared between the measured metabolites and the stand-
ards so they can be removed. In this paper we present a
new approach to normalization of metabolomics data
aiming to address these issues and develop a mathemati-
cal model that optimally assigns normalization factors for
each metabolite measured based on internal standard
profiles. We demonstrate the approach on mouse liver
lipid profiling using UPLC/MS, and compare its perform-
ance to two other commonly utilized approaches: nor-
malization by l2 vector norm and by retention time region
specific standard compounds. We discuss method per-
formance and several application possibilities.
Results and discussion
Formulation of the normalization model
The unnormalized metabolomics data resulting from first
stages of preprocessing, usually including peak detection
and alignment [17], can be represented by a matrix of N
variables (metabolite peaks) and M objects (samples). For
example, in liquid chromatography mass spectrometry
(LC/MS) based profiling; each peak is represented by mass
to charge ratio (m/z) and retention time (rt).
In the rest of the text we will use the following notation:
￿ i parameterizes peaks: i → {m/z, rt} and i = 1...N.
￿  s  parameterizes peaks from internal standard com-
pounds: s → {m/z, rt} and s = 1...S
￿ j parameterizes experiment runs: j = 1...M.
￿ X is N by M intensity matrix of metabolite peak profiles,
with elements Xij
￿ Z is S by M intensity matrix of standard compound peak
profiles, with elements Zsj.
Variation arising from the above mentioned sources is
often intensity (or metabolite concentration) dependent,
larger variation being associated with higher intensities.
The property that the magnitude of variation is not con-
stant is commonly referred to as heteroscedasticity. There-
fore, it is reasonable to assume a multiplicative model for
the observed intensities:
Xij = mi × rij (Z) × eij,   (1)
where mi the intensity independent of the run (i.e. true
intensity value), rij (function of Z) is the correction factor,
and eij the random error. We assume that the true intensity
value depends only on index i. In practice this assumption
means that we independently measure several samples
from one biological specimen (e.g. under repeatability
conditions). This assumption is crucial when the normal-
ization model is trained, i.e., when the parameters of the
model are learned from the data, but it can be relaxed
when the normalization is applied to a new set of data.
Reasons for this will become clear below.
The basic premise of our approach, abbreviated as NOMIS
method (Normalization using Optimal selection of Mul-
tiple Internal Standards), is that the systematic variation
in measured intensities Xij for an individual peak i can be
modeled as a function of variation of standard com-
pounds (Figure 2). Based on this assumption, the correc-
tion factors rij can be determined from the profiles of
standard compounds. We log transform the mulitiplica-
tive model of Equation (1)
Y = log X, Ω = log Z, μ = log m, ρ(Ω) = log r (Z), ε = log e
 (2)
to obtain an additive model:
Yij = μi + ρij(Ω) + εij.   (3)
The randomness in the values of Y is modeled by the error
ρij that is drawn from the normal distribution with zero
mean and variance  :
εij ~ N(0, ).    (4)
We aim at removing the effect of ρij in Equation (3) that
we presume to represent such variation in the data that
can be explained with changes in the levels of the standard
compounds. For the sake of simplicity, we treat the
observed values of the standards Ω as explanatory varia-
bles without modeling their error. We parameterize ρ as a
linear function of the levels of internal standards:
where the average   is taken over the samples j = 1...M, i.e.
. The parameters β therefore relate the
variability of internal standard intensities with the varia-
bility of intensities of endogenous metabolite peaks, i.e.
bigger the parameter βis, bigger is the contribution of
internal standard's s variability to the normalization cor-
rection factor of metabolite peak i.
From the equations (3–5) it follows that Yij can be mod-
eled as normally distributed,
σi
2
σi
2
ρβ ij is sj s
s
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Yij ~ N(μi + ρij, ),    (6)
therefore the log likelihood L of observing data Y under
the assumption of normality is
We note that the simple form of Equation (7) is due to the
assumption of independence of the random errors in
Equation (4), both across different sample measurements
and across different metabolites. While the former
assumption is easy to accept, the latter assumption is argu-
able, because it is well known that co-regulated metabo-
lites are highly correlated [18]. However, in order to keep
the number of parameters in the model moderate, we
decided to adhere to the latter assumption, being aware of
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Illustration of the basic principle of the normalization method Figure 2
Illustration of the basic principle of the normalization method. The normalization factor for each metabolite peak is 
influenced by the variability of each internal (IS) or external standard component and its association with the variability of the 
metabolite.
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its possible effect on the precision of the parameter esti-
mates [19].
We solve for the values of parameters μi, βis, and   that
maximize the log likelihood of observing the data:
Setting ∂ /∂μi = 0, ∂ /∂βis = 0, and ∂ /∂σi = 0 leads to
the following equations:
Since  , the Equation (9) leads to
μi = Yi..   (12)
The Equation (10) can be written as a matrix product:
where
correlates internal standards and endogenous metabolite
peaks, while
is a covariance matrix for the internal standards. Multiply-
ing each side of Equation (13) by the inverse of matrix Σ,
the estimates for the parameters β  can be written as a
product of two matrices:
where the hat notation means that the matrices are evalu-
ated using the actually observed data Y. Based on the mul-
tiplicative error model from Equation(1), the normalized
intensities for each peak are then calculated as
Once the model has been trained, i.e., the parameter β has
been estimated, it can be applied to a new data of samples
from a similar biological experiment with arbitrary true
metabolite levels, that is, in Equation 1 the true level, mij,
can be sample dependent.
Normalization in case of a single internal standard
In order to present an intuitive example of how the
NOMIS method works, we demonstrate it in a hypotheti-
cal case of a single internal standard. In this case the inten-
sity matrix of internal standard peaks Z is a 1 × M vector
(Z1j)j = 1..M and the Equations
(16) and (17) straightforwardly lead to:
where
We write the internal standard levels as
Log Z1j = C + ωj,   (21)
with C = Ω1. being the mean and ωj deviation of sample
j from the mean:
ωj =  Ω1j -  Ω1.. We model the endogenous metabolite
peaks as:
log Xij = Ti + βiωj + εij,   (22)
where Ti is the true log intensity of metabolite i's peak, βi
is a parameter that describes by how many units the log
intensity of peak i changes when the log intensity of the
standard increases by one unit, and εij is a random error
σi
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drawn from a normal distribution with zero mean. The
coefficients ri1 and   from Equations (19) and (20) can
then be written as
If we ignore the effect of the residual term in the ri1/
ratio:
then the Equation (18) reduces to
Where M = exp(C). From Equation (16) we see that βi = ci/
c11, with ci1 and c11 being estimators for the covariance
between metabolite i and the standard and the variance of
the standard respectively. The interpretation of the result
is now straightforward. For example, if βi = 1, i.e. the cov-
ariance of metabolite i with the standard is of the order of
the variance of the standard, then the Equation (26)
describes a simple correction by the internal standard
Such correction is commonly applied to specific metabo-
lites when their corresponding isotope labeled standards
are available. In contrast, if a specific metabolite is uncor-
related to the internal standard, βi = 0, and the normaliza-
tion factor is 1, leading to  ij = Xij. Thus, if the linear
association between a metabolite and the standard is
weak, the NOMIS method reduces the extent of normali-
zation.
In the following section we demonstrate the NOMIS
method using the multiple internal standard applications
in real biological samples.
Method performance and comparison to other methods: 
mouse liver lipidomics dataset
In order to evaluate the performance of the NOMIS
method, we performed UPLC/MS analysis of mouse liver
using lipidomics platform as described in Methods. We
run 16 replicates of the same biological sample in repeat-
ability conditions, corresponding to 3 different extracts of
10, 3, and 3 sample injections each, respectively. Total 5
internal standard compounds of distinct chemical and
functional characteristics were injected prior to extraction.
Total 1470 monoisotopic peaks were detected using
MZmine [20] software version 0.60. The processed dataset
with partial identification is available as Additional file 1
and the internal standards are listed in Table 1.
The performance of the NOMIS method is compared to
two other methods. The first is a commonly utilized nor-
malization by l2 vector norm (abbreviated as L2N) [10]:
where the average   is taken over the samples j = 1...M.
The second method is essentially the same as in [14],
based on the application of three internal standard com-
pounds (3STD) with the choices of retention time ranges
reflecting the analytical method used: LPC standard is
applied for peaks with rt < 300s, PC standard for 300s <rt
< 410s, and TAG standard for rt > 410s.
We utilize coefficient of variation (CV) as the main per-
formance measure for normalization methods. The CV is
defined as the ratio of the standard deviation and the
mean:
As the overall measure of variability we apply median CV:
MCV ≡ median {CVi}i =1...N   (30)
Distributions of CV for different normalization methods
for a liver lipidomics dataset are shown in Figure 3. The
distribution after application of NOMIS method is nota-
bly narrower, and the MCV is lower than in raw data or in
other normalization methods. Replacement of PC stand-
ard with PE in 3STD method did not alter the MCV, with
MCV = 0.282 for PE included, compared to MCV = 0.280
with PC. The CVs at individual peak level are shown in
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Figure 4 in a two-dimensional plot of m/z vs. the retention
time. One can clearly observe the variability drop across
the complete spectrum range for the NOMIS method. In
contrast, no specific improvement is observed for the L2N
method in any section of the spectrum. The 3STD method
performs particularly poorly in the region normalized by
the TAG standard, while in other two regions the improve-
ment appears only slight. The TAG standard was found
highly variable (Table 1), which we believe is a result of
the suppression effects due to high number of different tri-
acylglycerol species in that part of the spectrum. We
observed the same problem using the stable isotope
labeled external standard TG(16:0/16:0/16:0)13C3 (not
shown). Therefore, increased variability of the triacylglyc-
erol standard is not due to variability in sample extraction.
Heteroscedasticity
Calculation of the β matrix using the log transformation
is of potential concern because such transformation,
while efficient in correcting for heteroscedasticity, may
also amplify the high variability of low abundance metab-
olites [8,21]. The log transformation is also unable to deal
with value zero.
In order to study the effect of different normalization
methods on heteroscedasticity in data, we divided the
sorted mean intensity values for 1470 peaks into six bins
defined by the quantiles for the following cumulative
probabilities: P = [0.025, 0.25, 0.5, 0.75, 0.975]. The first
bin therefore contains the low abundance peaks on the
left tail of the intensity distribution, with cumulative
probability  p  < 0.025, the second contains peaks with
cumulative probability 0.025 = p < 0.25, etc. The median
coefficients of variance were calculated within each bin
and compared across different normalization methods
(Figure 5A). The CV for the low abundance peaks (p <
0.025) is expectedly highest as compared to other peaks
for the unnormalized data as well as for the three normal-
ization methods. The NOMIS method has the lowest MCV
within each bin, providing evidence that the use of log
transformation in calculation of the β matrix does not
lead to worse performance for low abundance metabolites
relative to the other normalization methods. This can be
also seen more directly in the scatter plot of CV and mean
values for the unnormalized and NOMIS normalized data
(Figure 5B).
We deal with the problem of zeros in log transformation
by utilizing the post-alignment peak picking algorithm
from the MZmine software [20]. In case of datasets uti-
lized in this paper no exact zeros were found among the
1470 peaks following such processing. Application of the
NOMIS method to selection of the internal standard mix-
ture. The systematic study of the results obtained by the
NOMIS method can also be utilized for selection of stand-
ard compound mixture used in the analytical method.
This may be useful in practical analytical work as more
standards do not necessarily guarantee better quality of
normalization. It is also important to gain understanding
of how each individual standard affects the variability of
individual molecular species across the full spectra.
To illustrate such an application of NOMIS, we normal-
ized the liver dataset described above using different com-
binations of the internal standards. Coefficients of
variance within a selected region of m/z and retention
time values, corresponding mainly to diacyl-phospholip-
ids, diacylglycerols and sphingolipids, are shown in Fig-
ure 6 for six such combinations. From the results one can
conclude that the removal of PE standard has the largest
negative effect on normalization performance, while the
Cer standard has least effect. However, the application of
all 5 standards still gives best results. The application of a
combination of three standards (LPC, PC, and TAG) per-
forms worse than any of the other combinations shown,
with median CV of 0.142. Interestingly, one spectral
region where this standard combination performs poorly
is for retention times of 3203–340s, where one can find
mainly the long fatty acid chain phosphatidylcholines
containing high total number of double bonds (see Addi-
tional file 1). Therefore, our results suggest the variability
(due to systematic error) of the saturated medium fatty
acid chain length PC used as a standard is different as for
the unsaturated long chain PCs, and therefore is not a
Table 1: Lipid internal standards The list of internal standards utilized in the demonstrations of the paper, their abbreviations, 
common names, amount in the sample, retention time in the UPLC/MS method described in the Methods, mean intensity as peak 
height, and coefficient of variance based on the 16-run liver repeatability study.
Abbreviation Name Amount (μg/sample) Retention time (s) Mean Intensity CV
LPC GPCho(17:0/0:0) 6.408 210 5574 0.118
Cer Cer(d18:1/17:0) 1.832 381 1044 0.197
PC GPCho(17:0/17:0) 0.198 388 521 0.111
PE GPEth(17:0/17:0) 1.790 392 316 0.134
TAG TG(17:0/17:0/17:0) 2.072 543 202 0.335BMC Bioinformatics 2007, 8:93 http://www.biomedcentral.com/1471-2105/8/93
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good standard for these components. Replacing PC with
PE in a three-standard combination (LPC, PE, and TAG)
leads to better performance of the NOMIS method, with
median CV of 0.127 (figure not shown).
While the variability of the TAG standard is high (CV =
0.335), its inclusion with the other standards still
improved the MCV from 0.129 to 0.116. The TAG stand-
ard in combination with other standards can therefore
model the variability of some metabolites better than the
four other standards alone. For example, the correlation
of the triacylglycerol levels with the TAG standard is
higher than with other standards. The median Pearson
correlation coefficient between the internal standard lev-
els and each of the 184 identified TAG species is 0.25,
compared to -0.30, 0.17, -0.18, and -0.08 for LPC, Cer,
PC, and PE standards, respectively.
The results from analysis of different internal standard
combinations above suggest the NOMIS method can be a
valuable tool in analytical development. Different biolog-
ical matrices and different analytical platforms may
require different combinations of standards for optimal
normalization and systematic evaluation of different
Coefficient of variance distributions for different normalization methods Figure 3
Coefficient of variance distributions for different normalization methods. Data shown is based on mouse liver run of 
16 samples under repeability conditions (3 extractions from the same biological sample, each with repeated runs of 10, 3, and 
3 injections, respectively). Total 1470 monoisotopic peaks were included in the analysis. The NOMIS method has a notably 
narrower CV distribution than raw data and other normalization methods, with lower median CV (MCV).BMC Bioinformatics 2007, 8:93 http://www.biomedcentral.com/1471-2105/8/93
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standards as illustrated above may provide the necessary
clues.
Investigation of the results in context of the identified 
molecular species
In order to gain insight into the nature of the NOMIS
method in the context of compounds studied, we identi-
fied several lipid molecular species in the dataset, 360 in
total. As expected, we found that the composition of the β
matrix correlates well with the composition of lipid func-
tional groups. The elements of β for each of the standards
are shown in Figure 7 for some of the most abundant rep-
resentative molecular species from different lipid classes.
The normalization factor, dependent both on the β matrix
and the internal standard concentration, is dominated by
the LPC standard for mono-acyl lipid species such as lys-
ophosphatidylcholines, lysophosphatidyletah-
nolamines, and monoacylglycerols. The sphingomyelin
species is affected mostly by a combination of the cera-
mide and PC standards, while the triacylglycerol normal-
ization factor curiously does not include the major
influence of the TAG standard. This may be largely due to
Coefficients of variance for individual peaks in liver repeatability study Figure 4
Coefficients of variance for individual peaks in liver repeatability study. Each peak detected is shown in the two 
dimensional plot of m/z vs. retention time plot, with the color corresponding to the coefficient of variance. The NOMIS 
method performs notably better in its ability to reduce the variability across the full spectrum. The 3STD method performs 
particularly poorly for higher retention times, where the normalization is based on triacylglycerol standard found to be highly 
variable (Table 1).BMC Bioinformatics 2007, 8:93 http://www.biomedcentral.com/1471-2105/8/93
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Effect of normalization methods on heteroscedasticity in the data Figure 5
Effect of normalization methods on heteroscedasticity in the data. (A) The sorted mean intensity values for 1470 
peaks are divided into six bins defined by the quantiles for the following cumulative probabilities: P= [0.025, 0.25, 0.5, 0.75, 
0.975]. The first bin therefore contains the low abundance peaks on the left tail of the intensity distribution, with cumulative 
probability p < 0.025. The median coefficients of variance were calculated within each bin. (B) Scatter plot of unnormalized and 
NOMIS normalized peaks. The solid curves, shown for all four methods compared, are drawn as guides using robust locally 
weighted regression and smoothing scatter plots method (LOWESS) [22] with the 100 variable window size smoothing kernel.
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high variability of the TAG standard, with matrix-effects
dominating the lipid class specific effects.
We also studied how the normalization by an internal
standard for a specific functional lipid group would com-
pare to normalization with the NOMIS method. We nor-
malized the identified lysophosphatidylcholine,
phosphatidylcholine, and triacylglycerol lipid species
with the LPC, PC, and TAG standards, respectively. As
shown in Table 2, the NOMIS method clearly outper-
forms the normalization of species from a specific molec-
ular class based on appropriate internal standard.
Normalization using β matrix obtained independently
The matrix β  relates the variability of each individual
metabolite with that of internal standards for a specific
platform and biological matrix. Therefore, it is possible
that the parameters β are obtained from a separate repeat-
ability experiment involving large number of repeated
measurements. This may often be desirable due to a large
number of normalization parameters N x (S + 2) deter-
mined by the method. The correction factors from Equa-
tion (17) in a real biological application then include the
matrix β obtained independently and the measured levels
of internal standards Ωsj from the biological experiment.
We tested this concept by utilizing the matrix β obtained
from 360 identified lipid species in the above described
16 sample run experiment in a new experiment in repeat-
ability conditions utilizing the same analytical platform
but different biological sample (3 extracts, 3 injections
each, i.e. total 9 sample runs). The results for the CVs for
The NOMIS method as a tool to select the best set of internal standards used for normalization Figure 6
The NOMIS method as a tool to select the best set of internal standards used for normalization. The coefficients 
of variation for different combinations of internal standards used in the NOMIS method as applied to the liver dataset (1470 
peaks). Only sub-region of m/z and retention times are shown, corresponding mainly to phospholipids, sphingolipids, and dia-
cylglycerols. The internal standard combinations are listed in the plot titles.BMC Bioinformatics 2007, 8:93 http://www.biomedcentral.com/1471-2105/8/93
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individual peaks are shown in Figure 8. Even in that case
the NOMIS method outperformed the others, even
though the differences as judged by median CV within
each dataset were small.
These results provide evidence that the NOMIS method
may also be used to develop a "reusable" β matrix for
studies utilizing the same biological matrix and analytical
platform. As evident from Equation
The β matrix values for selected liver lipid components Figure 7
The β matrix values for selected liver lipid components. The β matrix values are shown for 8 illustrative lipid molecular 
species of different functional class and for all internal standards used (abbreviated as shown in Table 1). The LPC has expect-
edly high influence on monoacyl lipids. As one would have expected based on chemical structure, the sphingomyelin, which 
does not have its own class-specific internal standard, is influenced most by ceramide (Cer) and phosphatidylcholine (PC) 
standardsBMC Bioinformatics 2007, 8:93 http://www.biomedcentral.com/1471-2105/8/93
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(16) (16) and demonstrated in Figure 7 for the case of lip-
ids, the β  matrix captures the variation of all detected
metabolites in biological matrix as modeled by selected
standard compounds. In case of repeatability runs dem-
onstrated in this paper, the variability modeled is due to
the obscure variation introduced in experimental studies of
metabolites. We therefore believe the best usage of the
NOMIS method should include a large run in repeatabil-
ity conditions for a specific platform and specific biologi-
cal matrix (i.e. biofluid or tissue type) in order to obtain a
β matrix, which would then be applied to normalization
of other samples using the same standard compounds and
peak lists. The latter requires that the analytical method is
sufficiently accurate and precise so that one can reliably
track a specific set of peaks within a specific biological
matrix even if some peaks remain unidentified. The β
matrix may even be updated when new runs are made and
we believe there are opportunities to develop sophisti-
cated probabilistic methods to model and update the β
matrix based on new experimental data.
The NOMIS normalization model is derived from the var-
iabilities and correlation structure observed in data meas-
ured under repeatability conditions and does not
specifically model different sources of systematic varia-
tion, incl. ion suppression. Therefore, as long as the
assumption of multiplicative error model is valid to a rea-
sonable extent, the NOMIS approach may be applicable.
The heteroscedasticity of GC/MS spectra has in fact
already been studied and demonstrated earlier [21]. We
therefore believe the NOMIS approach may be applicable
to analytical platforms other than LC/MS demonstrated in
this paper.
Conclusion
We introduced a new method for normalization of metab-
olomics data which utilizes variability information from
multiple internal standard compounds to find optimal
normalization factor for each individual molecular spe-
cies detected (NOMIS). The method proved superior to
two other commonly utilized normalization strategies in
its ability to reduce variability across the full spectrum of
metabolites.
The NOMIS method can be used directly as a one-step
normalization method or as a two-step method where the
normalization parameters containing information about
the variabilities of internal standard compounds and their
association to variabilities of metabolites are first calcu-
lated from a study carried in repeatability conditions.
Additionally, the method can be used to select standard
compounds for normalization and evaluate their influ-
ence on variability of all detected metabolites.
While we focused on applications of NOMIS to LC/MS
based approaches; we believe the same strategy can be
applied to other analytical platforms used in metabo-
lomics, as well as to other levels of molecular profiling
such as mass spectrometry based proteomics.
Methods
Liver LC/MS based lipid profiling
An aliquot of 20 μl of an internal standard mixture (5 ref-
erence compounds at concentration level 83–10 μg/ml),
50 μl of 0.15 M sodium chloride and chloroform: metha-
nol (2:1) (200 μl) was added to the tissue sample (203–
30 mg). The sample was homogenized, vortexed (2 min)
let to stand (1 hour for liver) and centrifuged at 10000
RPM for 3 min. From the separated lower phase, an aliq-
uot was mixed with 10 μl of a labelled standard mixture
(3 stable isotope labelled reference compounds at concen-
tration level 93–11 μg/ml) and 0.53–1.0 μl injection was
used for LC/MS analysis.
Total lipid extracts were analysed on a Waters Q-Tof Pre-
mier mass spectrometer combined with an Acquity Ultra
Performance LC™ (UPLC). The column, which was kept at
50°C, was an Acquity UPLCTM BEH C18 10 × 50 mm
with 1.7 μm particles. The binary solvent system (flow rate
0.200 ml/min) included A. water (1% 1 M NH4Ac, 0.1%
HCOOH) and B. LC/MS grade (Rathburn) acetonitrile/
isopropanol (5:2, 1% 1 M NH4Ac, 0.1% HCOOH). The
gradient started from 65% A/35% B, reached 100% B in 6
min and remained there for the next 7 min. The total run
time per sample, including a 5 min re-equilibration step,
was 18 min. The temperature of the sample organizer was
set at 10°C.
Mass spectrometry was carried out on Q-Tof Premier
(Waters, Inc.) run in ESI+ mode. The data was collected
over the mass range of m/z 3003–1600 with a scan dura-
tion of 0.08 sec. The source temperature was set at 120°C
Table 2: Comparison of coefficients of variance for three lipid classes The raw data variability for identified lipid species of the same 
class is compared to the results from the NOMIS method, as well as to results adjusted for an internal standard of the same class.
Raw data NOMIS Internal standard
Lysophosphatidylcholines (N = 13) 0.245 0.094 0.221
Phosphatidylcholines (N = 74) 0.183 0.100 0.209
Triacylglycerols (N = 184) 0.227 0.146 0.308BMC Bioinformatics 2007, 8:93 http://www.biomedcentral.com/1471-2105/8/93
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and nitrogen was used as desolvation gas (800 L/h) at
250°C. The voltages of the sampling cone and capillary
were 39 V and 3.2 kV respectively and collision energy 5
V, respectively. Reserpine (50 μg/L) was used as the lock
spray reference compound (10 μl/min; 10 sec scan fre-
quency).
Data processing including peak detection, alignment, and
de-isotoping, was performed using the MZmine software
version 0.60 [17]. Identification was performed based on
an internal reference database of lipid species. The imple-
mentation of normalization methods and data analysis
were performed using Matlab version 7.2 (Mathworks,
Inc.).
Abbreviations
MS: Mass spectrometry.
UPLC™: Ultra Performance Mass Spectrometry (Waters,
Inc.).
LC/MS: Liquid chromatography – mass spectrometry.
Coefficients of variance for identified liver lipid species Figure 8
Coefficients of variance for identified liver lipid species. Each lipid molecular species is shown in the two dimensional 
plot of m/z vs. retention time plot, with the color corresponding to the coefficient of variance. The data is based on normaliza-
tion performed on a different biological sample as in Figure 4, which was run 9 times (3 extractions, with 3 injections each). 
Total 360 identified lipid molecular species were included in the analysis. The NOMIS method utilized the β matrix calculated 
previously from a 16-sample run (Figure 4).BMC Bioinformatics 2007, 8:93 http://www.biomedcentral.com/1471-2105/8/93
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GC/MS: Gas chromatography – mass spectrometry.
QTof: Quadrupole – time of flight mass spectrometer.
CV: Coefficient of variance.
MCV: Median coefficient of variance.
m/z: Mass-to-charge ratio (m is molecular mass and z is
charge of the ion).
NOMIS: Normalization using Optimal selection of Multi-
ple Internal Standards (the method introduced in this
paper).
3STD: Normalization by retention-time-region-specific
standard compounds.
L2N: Sum of squares normalization.
LPC: lysophosphatidylcholine
Cer: ceramide
PC: phosphatidylcholine
PE: phosphatidylethanolamine
TAG: triacylglycerol
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